


ERS 2026 Preview – Clinical and AI / ML



LucidQuest Intelligence
Accelerate your success



ERS 2026 Preview – Table of Contents

• <u>New Trends in Respiratory Disease Treatment Strategy At ERS'26</u>	<u>3-5</u>
• <u>Key Sessions To Watch</u>	<u>6</u>
• <u>Industry-sponsored Sessions & Focus Areas At ERS 2026</u>	<u>7-14</u>
• <u>Competitive Landscape At a Glance at ERS 2026</u>	<u>8-9</u>
• <u>Key Industry-sponsored Sessions At ERS 2026</u>	<u>10-14</u>
• <u>New Entrants</u>	<u>15</u>
• <u>AI/ML Trends & Strategic Watchpoints At ERS 2026</u>	<u>16-18</u>
• <u>AI / Digital Health Angle At ERS 2026</u>	<u>17-18</u>
• <u>What We're Watching For Post-congress</u>	<u>19</u>
• <u>Get In Touch With LucidQuest</u>	<u>20</u>



ERS 2026 – New Trends in Respiratory Disease Treatment Strategy (1/3)



• **Will COPD treatment become more biologically segmented?**

- ERS 2026 will present late-stage and mechanistic evidence across IL-33, IL-5, TSLP/Type 2 inflammation and dual PDE3/4 inhibition, alongside established inhaled treatment strategies. The competitive question will be whether these approaches begin to define clearer treatment-responsive COPD populations and more targeted intervention strategies, or add further therapeutic options without resolving how patients should ultimately be selected and sequenced



• **Will severe asthma differentiation shift toward pathway breadth, durability and remission?**

- Data across TSLP/TSLPR, IL-5/IL-5R and emerging multi-pathway approaches will place different strategies for controlling airway inflammation in focus. The key question will be whether future differentiation is increasingly driven by upstream pathway targeting, sustained clinical response, remission and reduced treatment frequency rather than incremental differences in conventional efficacy outcomes alone





• **Can bronchiectasis move beyond predominantly infection-directed management?**

- ERS 2026 will bring together evidence around **brensocatib, neutrophil biology, inhaled antibiotics and Pseudomonas eradication**, reflecting different approaches to the underlying drivers and consequences of bronchiectasis. The central question will be whether **targeting neutrophil-mediated inflammation establishes a meaningful disease-modifying treatment layer** alongside, rather than replacing, microbiology-directed and infection-focused management



• **Will pulmonary fibrosis competition increasingly depend on mechanism and patient selection?**

- Data across **nerandomilast, inhaled treprostinil and other emerging antifibrotic approaches** will be presented across IPF and progressive pulmonary fibrosis, including analyses in **clinically distinct patient groups**. The strategic question will be how these approaches differentiate by **disease phenotype, baseline severity, clinical outcomes** and their potential role alongside or within evolving antifibrotic treatment strategies



• **Will PAH increasingly become a sequencing and combination challenge?**

- ERS 2026 will feature evidence across **activin-signalling inhibition, prostacyclin-pathway therapy and emerging approaches including serralutinib**, with clinical, haemodynamic, imaging and longer-term analyses represented across the programme. The key question will be whether these mechanisms establish **clearer positions within the PAH treatment pathway** or increase the need for evidence defining when different therapeutic approaches should be introduced, combined or sequenced



• **Can AATD treatment move closer to correcting the underlying biological defect?**

- The programme will bring together AAT restoration, in-vivo gene editing and approaches addressing both pulmonary and hepatic manifestations of **alpha-1 antitrypsin deficiency**. ERS 2026 will therefore test whether AATD development is beginning to move upstream from management of disease consequences toward **restoration or correction of the underlying deficiency**, potentially changing how future therapies are differentiated





Key Sessions To Watch

Date	Session Title (short)	Type	Author / Institution	Why Watch
06 Sep 2026	Tozorakimab: FRONTIER-4 COPD Airway Biology	Late-Breaking Oral	G. De Palo	Provides mechanistic evidence around targeted inflammatory intervention in COPD
06 Sep 2026	Ralinepag: ADVANCE Outcomes in PAH	Late-Breaking Oral	M. Humbert	Important test of the prostacyclin pathway within an increasingly multi-pathway PAH landscape
06 Sep 2026	Long-Term Sotatercept: SOTERIA	Oral	I. Preston	Will provide longer-term evidence around activin-signalling inhibition in PAH
06 Sep 2026	Molgramostim: IMPALA-2 Long-Term Data	Oral	B. Trapnell	Helps define durability and longer-term treatment potential in aPAP
07 Sep 2026	Nerandomilast by Baseline FVC: FIBRONEER	Oral	M. Wijsenbeek	Could help clarify patient selection within pulmonary fibrosis
07 Sep 2026	TezEx: Severe Asthma Exacerbation Biology	Late-Breaking Oral	F. Haris	Examines residual exacerbation biology despite tezepelumab treatment
08 Sep 2026	Tozorakimab: OBERON & TITANIA Phase 3	Late-Breaking Clinical Trial	F. Sciurba	One of the major COPD readouts for evaluating targeted inflammatory therapy
08 Sep 2026	VALIANT: Verekitug in Severe Asthma	Late-Breaking Oral	M. Wechsler	Tests TSLP-receptor antagonism as another approach to upstream airway inflammation
08 Sep 2026	BEAM-302 First-in-Human Gene Editing in AATD	Late-Breaking Oral	J. Hurst	Provides an early clinical test of in-vivo genetic correction in AATD

Industry-Sponsored Sessions & Focus Areas – ERS 2026





ERS 2026– Competitive Landscape at a Glance (1/2)

Name	Sessions	Companies / Assets	Why It Matters
COPD biologics and novel inflammatory targets	Multiple	Tozorakimab; mepolizumab; ensifentrine; PRT-089Q01	Phase 3, late-breaking and mechanistic data will test whether COPD treatment can become more targeted around inflammatory biology and defined patient subgroups
Severe asthma: upstream targeting and durable control	Multiple	Verekitug; lunsekimig; tezepelumab; depemokimab; GB-0895	Multiple approaches will compete on pathway breadth, durability, remission and treatment frequency as severe asthma biologic choice becomes more complex.
Bronchiectasis: inflammation and infection control	Multiple	Brensocatib; inhaled tobramycin; Pseudomonas eradication strategies	The programme will test how neutrophil-directed treatment can be integrated with infection-focused approaches in bronchiectasis management
Pulmonary fibrosis: expanding therapeutic mechanisms	Multiple	Nerandomilast; inhaled treprostinil; buloxibutid; GRI-0621; HSK44459	A broader pipeline across IPF and PPF will increase the importance of defining which mechanisms fit which patients and disease stages.



ERS 2026– Competitive Landscape at a Glance (2/2)

Name	Sessions	Companies / Assets	Why It Matters
PAH: multi-pathway treatment and sequencing	Multiple	Sotatercept; ralinepag; serralutinib; TPIP	Evidence across activin and prostacyclin-related approaches will sharpen questions around earlier intervention, combination and treatment sequencing
AATD: restoration and genetic correction	Multiple	BEAM-302; AAT restoration approaches	First-in-human gene-editing data and restoration-focused sessions will test how far AATD treatment can move toward addressing the underlying deficiency
aPAP: targeted disease management	Multiple	Molgramostim; IMPALA-2	Longer-term efficacy and safety evidence will help define the role of mechanism-based treatment in autoimmune pulmonary alveolar proteinosis



Key Industry-Sponsored Sessions at ERS 2026 (1/5)



• AstraZeneca:

- Focus Areas: COPD, Severe Asthma, IL-33 & Epithelial-Driven Inflammation
- Presentations will focus on inflammatory drivers across COPD and severe asthma, including IL-33, TSLP and eosinophilic inflammation. The sessions will examine whether targeting different points in airway inflammation can support more precise treatment across obstructive and eosinophilic respiratory disease



• GSK:

- Focus Areas: Severe Asthma, COPD & Sustained Disease Control
- Sessions will focus on rapid and durable asthma control, mepolizumab in COPD, treatment escalation and longer-acting therapeutic approaches. The programme will examine how sustained efficacy and reduced treatment burden could differentiate therapy across severe asthma and COPD



Key Industry-Sponsored Sessions at ERS 2026 (2/5)



• Grifols:

- Focus Areas: [Early COPD, Bronchiectasis, AATD & Quantitative Imaging](#)
- Sessions will focus on [earlier COPD, quantitative CT and disease progression](#) across COPD, bronchiectasis and AATD. The programme will explore whether [earlier identification and more objective disease assessment](#) can improve patient stratification and long-term management



• Pfizer:

- Focus Areas: [RSV, Pneumococcal Disease & Respiratory Infection Prevention](#)
- Presentations will focus on [RSV and pneumococcal prevention in adults](#), including patients with chronic respiratory disease. The sessions will examine the role of [vaccination in reducing infection-related burden](#) within populations vulnerable to respiratory deterioration



Key Industry-Sponsored Sessions at ERS 2026 (3/5)

- **Insmed:**

- Focus Areas: **Bronchiectasis, Neutrophilic Inflammation & NTM Lung Disease**
- Presentations will focus on **earlier bronchiectasis recognition, neutrophil-driven disease biology and precision management of NTM lung disease**. The sessions will examine whether **more targeted approaches** can move these difficult-to-treat respiratory diseases toward **earlier and more disease-directed intervention**

- **Boehringer Ingelheim:**

- Focus Areas: **Pulmonary Fibrosis, Earlier Recognition & Treatment Initiation**
- Sessions will focus on improving outcomes in **pulmonary fibrosis, including earlier diagnosis and overcoming barriers to timely treatment**. The programme will reinforce the importance of **identifying and treating patients** earlier as pulmonary fibrosis management becomes more complex



Key Industry-Sponsored Sessions at ERS 2026 (4/5)



• Chiesi:

- Focus Areas: COPD, Asthma & Inhaled Treatment Optimization
- Presentations will focus on **earlier COPD intervention, small-airway disease and evolving asthma strategies, including triple therapy and remission**. The sessions will examine **how earlier intervention and optimized inhaled treatment** could improve disease control across asthma and COPD



• Ferrer:

- Focus Areas: **IPF, Inhaled Treprostinil & TETON Phase 3**
- Presentations will focus on the **final TETON Phase 3 programme** and the **potential role of inhaled treprostinil in IPF**. The sessions will help assess whether this approach can establish a **differentiated position within the evolving pulmonary fibrosis treatment landscape**



Key Industry-Sponsored Sessions at ERS 2026 (5/5)

- **Sanofi / Regeneron:**

- Focus Areas: Type 2 Asthma, COPD & Unified Airway Disease
- Presentations will focus on Type 2 inflammation across asthma, COPD and CRSwNP, including patient identification and disease phenotyping. The sessions will examine how a Type 2-directed approach can extend across different but biologically connected airway diseases

- **MSD:**

- Focus Areas: PAH Treatment Strategy & COPD PDE3/PDE4 Inhibition
- Sessions will focus on earlier use of novel therapy in PAH, sotatercept and PDE3/PDE4 inhibition with ensifentrine in COPD. The programme will explore treatment timing in PAH while examining a distinct anti-inflammatory approach to COPD management



New Entrants

Asset / Company	2026 Presence
BEAM-302	Late Breaking Abstract - First-in-human in vivo gene editing for severe alpha-1 antitrypsin deficiency (AATD): initial data from the Phase 1/2 study of BEAM-302
PRT-089Q01	Late Breaking Abstract - PRT-089Q01, an IND-enabling anti-interleukin-33 antibody, represents a potential best-in-class agent for chronic obstructive pulmonary disease
GRI-0621	Late Breaking Abstract - Safety, translational biomarkers and lung function with the oral RAR β / γ -selective agonist GRI-0621 in idiopathic pulmonary fibrosis: a Phase 2a randomised, double-blind, placebo-controlled trial (GRI-0621-IPF-02)
PRT-089Q01	Late Breaking Abstract - PRT-089Q01, an IND-enabling anti-interleukin-33 antibody, represents a potential best-in-class agent for chronic obstructive pulmonary disease
Verekitug	Late Breaking Abstract - VALIANT: a phase 2 trial of the efficacy and safety of verekitug, a thymic stromal lymphopoietin (TSLP) receptor antagonist, for severe asthma
Lunsekimig	RCT Abstract - Lunsekimig for patients with moderate-to-severe asthma: results from the AIRCULES trial
DeepSpiro	Late Breaking Abstract - DeepSpiro: Smartphone-Based Lung Function Estimation From Forced-Exhalation Sound — A Multicenter Development and Validation Study
NodeAI	Late Breaking Abstract - Feasibility and diagnostic performance of NodeAI for real-time prediction of mediastinal lymph node malignancy during EBUS for lung cancer staging





AI / Digital Health Angle at ERS 2026 (1/2)

- **AI and digital-health presentations at ERS 2026 will centre on earlier disease recognition, diagnostic support, physiological assessment and image-based disease characterisation. Sessions covering smartphone-derived lung-function estimation, AI-assisted lung imaging and real-time assessment during EBUS suggest that digital tools are increasingly being tested at specific points in the respiratory diagnostic pathway**
- **The strategic question will be whether these technologies can move beyond technical validation and provide information that is useful enough to influence routine clinical assessment. Of particular interest will be their potential to support earlier detection, reduce diagnostic uncertainty and generate more objective measures of respiratory disease and treatment response.**
- **Key sessions include:**
 - DeepSpiro: Smartphone-Based Lung Function Estimation From Forced-Exhalation Sound - A Multicenter Development and Validation Study
 - Feasibility and diagnostic performance of NodeAI for real-time prediction of mediastinal lymph node malignancy during EBUS for lung cancer staging
 - Earlier Recognition of ILD: Combining Clinical Expertise and Artificial Intelligence
 - Artificial Intelligence for Lung Imaging: Supporting Earlier Detection
 - Taladegib Phase 2a post-hoc CT analysis using Brainomix e-Lung



AI / Digital Health Angle at ERS 2026 (2/2)

- **Sessions suggest AI and digital tools are increasingly being used to improve:**
 - Earlier disease recognition through AI-supported lung imaging, particularly in interstitial lung disease
 - Accessible respiratory assessment through smartphone-based estimation of lung function from forced-exhalation sounds
 - Real-time diagnostic support through AI-assisted prediction of mediastinal lymph-node malignancy during EBUS
 - Quantitative disease characterisation through imaging-derived measures of structural lung abnormalities and disease progression
 - Treatment-response assessment and evidence generation through incorporation of quantitative imaging into respiratory clinical studies



What We're Watching for Post-ERS 2026

- Whether [tozorakimab](#) data from [OBERON](#), [TITANIA](#) and [FRONTIER-4](#) provide enough [clinical and mechanistic evidence](#) to define a clearer role for targeted inflammatory treatment in COPD.
- Whether [verekitug](#), [lunsekimig](#), [tezepelumab](#) and [depemokimab](#) show enough differentiation in [durability, remission, exacerbation control and dosing frequency](#) to influence future severe-asthma treatment choices
- Whether [nerandomilast](#), inhaled [treprostinil](#), [buloxibutid](#) and other [pulmonary-fibrosis programmes](#) begin to establish clearer treatment positioning across IPF and progressive pulmonary fibrosis
- Whether [sotatercept](#), [ralinepag](#) and [seralutinib](#) provide enough evidence to clarify [earlier intervention, combination and sequencing strategies](#) in PAH.
- Whether [brensocatib](#)-related analyses, [neutrophil biology](#) and inhaled [tobramycin/Pseudomonas eradication](#) data help define how [inflammation-directed and infection-directed treatment](#) could be integrated in bronchiectasis

Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM